Dr Pierce, formerly Merck, and now OncoSec CMO has changed that.
DD Longs that understand the impact of a Dr. Pierce would be adding more shares in a "Buy, Hold, Accumulate" investment strategy.
In addition this 2013 achieved milestone is directly related to Dr. Pierce's Clinical Trials with Merck.
I look forward to the "Biotech Showcase" on Jan 14 to hear more details about ImmunoPulse in combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 therapies and what studies/trials OncoSec has planned. This is a major pursuit by OncoSec for humans skin cancers therapies and Dr. Pierce is leading the way for OncoSec.